

Reconciliation of Non-GAAP Adjusted EBITDA				
(in millions)				
	Three Months Ended	Three Months Ended	Six Months Ended	Six Months Ended
	June 30, 2022	June 30, 2021	June 30, 2022	June 30, 2021
Net Loss	(\$903.0)	(\$29.5)	(\$963.9)	(\$54.1)
Interest Expense, Net	2.7	2.4	5.5	4.5
Depreciation and Amortization Expense	21.7	0.4	43.5	0.8
Goodwill Impairment	851.5	0.0	851.5	-
Mark-To-Market Adjustment For Stock Warrants	(11.8)	1.1	(6.0)	10.6
Premium Deficiency Reserve	(1.5)	1.0	(2.8)	3.0
Transaction Expense, Business Combinations	1.0	-	2.1	-
Transaction Related Litigation Expense	1.1	-	1.1	-
Transaction Bonuses	5.9	-	5.9	-
Stock-Based Compensation	3.7	0.6	15.4	1.0
Other	0.1	-	0.1	-
EBITDA, Adjusted	(\$28.6)	(\$24.0)	(\$47.6)	(\$34.2)

Reconciliation of non-GAAP adjusted EBITDA / PMPM				
(in PMPM \$)				
	Three Months Ended	Three Months Ended	Six Months Ended	Six Months Ended
	June 30, 2022	June 30, 2021	June 30, 2022	June 30, 2021
Net Loss	(\$2,959.7)	(\$147)	(\$1,580)	(\$135)
Interest Expense, Net	\$8.8	12	9	11
Depreciation and Amortization Expense	\$71.1	2	71	2
Goodwill Impairment	\$2,790.9	0	1,396	-
Mark-To-Market Adjustment For Stock Warrants	(\$38.7)	5	(10)	26
Premium Deficiency Reserve	(\$4.9)	5	(5)	7
Transaction Expense, Business Combinations	\$3.3	-	3	-
Transaction Related Litigation Expense	\$3.6	-	2	-
Transaction Bonuses	\$19.3	-	10	-
Stock-Based Compensation	\$12.1	3	25	2
Other	\$0.3	-	0	-
EBITDA, Adjusted	(\$94)	(\$119)	(\$78)	(\$85)

**Reconciliation of non-GAAP adjusted EBITDA / PMPM
(in PMPM \$)**

'For the Year Ended

December 31, 2021

Net Loss	(\$254.2)
Interest Expense, Net	\$13.7
Depreciation and Amortization Expense	\$10.9
Goodwill Impairment	\$0.0
Mark-To-Market Adjustment For Stock Warrants	\$6.7
Premium Deficiency Reserve	\$47.1
Transaction Expense, Business Combinations	\$36.9
Transaction Related Litigation Expense	\$9.9
Transaction Bonuses	\$0.0
Stock-Based Compensation	\$10.4
Other	\$0.0
EBITDA, Adjusted	(\$119)